Do You Believe in Phreesia’s (PHR) Strong Upside Potential?

1 hour ago 2

Soumya Eswaran

Thu, June 4, 2026 astatine 8:19 AM CDT 3 min read

Cambiar SMID Fund, managed by Cambiar Investors, published its Q1 2026 capitalist letter. A transcript of the missive is disposable to download here. The capitalist people (CAMMX) returned 2.21%, and the organization people (CAMUX) returned 2.27%, underperforming the Russell 2500 Value Index's 4.77%. This shortfall was chiefly owed to declines successful definite healthcare and concern positions and little vulnerability to the top-performing Energy sector. The broader US equity marketplace saw mixed results, with the S&P Index down 4.3% and the Russell 2000 up 0.9%. Economic headwinds included Mag 7 stocks’ precocious capex budgets, AI disruption fears, and redemption gates successful backstage credit, exacerbated by the struggle successful Iran, starring to a wide driblet successful banal prices. Notably, worth stocks outperformed maturation stocks successful the quarter, offering immoderate downside protection. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2026.

In its first-quarter 2026 capitalist letter, Cambiar SMID Fund highlighted stocks similar Phreesia, Inc. (NYSE:PHR). Phreesia, Inc. (NYSE:PHR) is simply a healthcare exertion institution that offers an integrated SaaS-based bundle and outgo level for the healthcare industry. On June 3, 2026, Phreesia, Inc. (NYSE:PHR) closed astatine $9.65 per share. One-month instrumentality of Phreesia, Inc. (NYSE:PHR) was -1.83%, and its shares mislaid 62.57% implicit the past 52 weeks. Phreesia, Inc. (NYSE:PHR) has a marketplace capitalization of $596.48 million.

Cambiar SMID Fund stated the pursuing regarding Phreesia, Inc. (NYSE:PHR) successful its Q1 2026 capitalist letter:

"Security enactment wrong Healthcare comprised the largest resistance connected show successful the quarter, arsenic Solventum and Phreesia, Inc. (NYSE:PHR) each incurred sizable drawdowns. AI disruption fears besides contributed to the drawdown successful Phreesia, which is simply a bundle supplier with a cardinal niche successful the healthcare space. The company’s in-patient registration/check-in services and integer engagement level are well-entrenched successful infirmary networks and specialty practices. Some of the symptom successful the banal was successful effect to a guide-down successful advertizing revenue, arsenic customers specified arsenic vaccine providers and GLP-1 companies person scaled backmost their spending. With that said, Phreesia maintained their full-year EBITDA guidance, pointing to continued lawsuit maturation and stronger pricing. With a beardown equilibrium expanse and lawsuit basal of implicit 5K providers/100K physicians, we judge that Phreesia offers beardown upside imaginable from existent levels."

15 Countries with the Highest Rates of Lung Cancer

Phreesia, Inc. (NYSE:PHR) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 31 hedge money portfolios held Phreesia, Inc. (NYSE:PHR) astatine the extremity of the archetypal 4th fiscal 2027, up from 36 successful the erstwhile quarter. Phreesia, Inc. (NYSE:PHR) reported full gross of $130.9 million, marking an summation of 13% year-over-year. While we admit the imaginable of Phreesia, Inc. (NYSE:PHR) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article